{"id":525798,"date":"2021-08-10T07:04:15","date_gmt":"2021-08-10T11:04:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/"},"modified":"2021-08-10T07:04:15","modified_gmt":"2021-08-10T11:04:15","slug":"eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","title":{"rendered":"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., Aug.  10, 2021  (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021.<\/p>\n<p align=\"left\">The presentation will be available for on-demand viewing beginning August 17, 2021 at 9:00 a.m. ET via the Investors section of the Company website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cz1e7nWAKcLukhEnqR1AOkpp6vyUxHOWAX2AHYA6xqycIbEquZ-3hRq6MulG_sniffYB616d-RRer9xTvsdRyoZmfoUEAOUpr5uNRO9p6bQ=\" rel=\"nofollow noopener\" target=\"_blank\">www.eyepointpharma.com<\/a>. The replay will be available for 90 days after the event.<\/p>\n<p align=\"left\">\n        <strong>About EyePoint Pharmaceuticals, Inc.<\/strong>\u00a0(Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company&#8217;s pipeline leverages its proprietary Durasert<sup>\u00ae<\/sup> technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ<sup>\u00ae<\/sup>, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU<sup>\u00ae<\/sup>, for the treatment of postoperative inflammation following ocular surgery.\u00a0EyePoint Pharmaceuticals\u00a0is headquartered in\u00a0Watertown,\u00a0Massachusetts. To learn more about the Company, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cz1e7nWAKcLukhEnqR1AOkpp6vyUxHOWAX2AHYA6xqwtgZwMEf6fu-867iBUkct-_kXmjb_qHNLPKdWOqU9IZ6VcL6P_x8S-Mv7WZ1HaW9g=\" rel=\"nofollow noopener\" target=\"_blank\">www.eyepointpharma.com<\/a>\u00a0and connect on Twitter and LinkedIn.<\/p>\n<p align=\"left\">\n        <strong>Investors:<\/strong>\n      <\/p>\n<p align=\"left\">Christina Tartaglia<br \/>Stern IR<br \/>Direct: 212-698-8700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wUD10P4S5I0QonnDsreGJ57Z8XdIYP9g5y9ev5C9X22aCLmIrhI3nKC2EA3G03NnyWSjAkhhpIRIQD1cy97W_1X2Usi8BUwUpagf7PgKhl2NwGIey2rQMabkdrj2oBb9\" rel=\"nofollow noopener\" target=\"_blank\">christina.tartaglia@sternir.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p align=\"left\">Green Room Public Relations<br \/>Stephanie Jacobson <br \/>Green Room Communications<br \/>Direct: 610-420-3049 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w4vDXRJ9d-LajfYUXBQivuDNr1IsZvaJu_B5DoDN_fUD1ev7oT3v6NfQJuW7v4xiPZXmnwVX4bx4ByuEB2KhenG339qa_89YhRalJXtsgDE=\" rel=\"nofollow noopener\" target=\"_blank\">sjacobson@greenroompr.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWQwMTgyNTYtM2Q5OS00M2QzLTkxOTMtNDJhZmQ5ODkxYTRkLTEwMTczOTA=\/tiny\/EyePoint-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021. The presentation will be available for on-demand viewing beginning August 17, 2021 at 9:00 a.m. ET via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event. About EyePoint Pharmaceuticals, Inc.\u00a0(Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-525798","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021. The presentation will be available for on-demand viewing beginning August 17, 2021 at 9:00 a.m. ET via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event. About EyePoint Pharmaceuticals, Inc.\u00a0(Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with &hellip; Continue reading &quot;EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-10T11:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference\",\"datePublished\":\"2021-08-10T11:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\"},\"wordCount\":242,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\",\"name\":\"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=\",\"datePublished\":\"2021-08-10T11:04:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference - Market Newsdesk","og_description":"WATERTOWN, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021. The presentation will be available for on-demand viewing beginning August 17, 2021 at 9:00 a.m. ET via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event. About EyePoint Pharmaceuticals, Inc.\u00a0(Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with &hellip; Continue reading \"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-10T11:04:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference","datePublished":"2021-08-10T11:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/"},"wordCount":242,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","name":"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=","datePublished":"2021-08-10T11:04:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTg0MCM0MzQ5Njg4IzIwMDU4MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=525798"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525798\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=525798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=525798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=525798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}